Clinical Trials Logo

Clinical Trial Summary

Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of disease remain unclear.

This observational multicenter cohort study is designed to study the occurrence of Carcinoid Heart Disease in patients with differentiated carcinoid tumors, to describe numerous factors influencing the occurrence, severity, progression and long-term survival of patients with Carcinoid Heart Disease. Basic informations and detailed diagnosis informations (oncological and cardiac parameters), are collected by professional doctors. Clinical outcomes (onset of Carcinoid Heart Disease, cardiac surgery, related death) will be followed up every year or every six/three months if clinically indicated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03498040
Study type Observational
Source Hospices Civils de Lyon
Contact Catherine LOMBARD-BOHAS, Dr
Phone 04 72 11 91 67
Email catherine.lombard@chu-lyon.fr
Status Not yet recruiting
Phase
Start date April 2018
Completion date April 2033

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04039516 - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Phase 2
Active, not recruiting NCT05064514 - Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease N/A
Withdrawn NCT04065165 - Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Phase 3